Free Testosterone Rate-of-Change Interpretation: What Your Lab Trend Actually Means

Why Free Testosterone Matters More Than Total Testosterone

Total testosterone includes hormone bound to sex hormone-binding globulin (SHBG), which is biologically inactive, as well as hormone loosely bound to albumin and the small unbound fraction. Only the unbound fraction, roughly 1 to 4% of total testosterone in men, crosses cell membranes and activates androgen receptors directly.

SHBG concentrations vary enormously between individuals and shift with age, insulin resistance, thyroid status, liver function, and exogenous hormones. Two men can have identical total testosterone values of 550 ng/dL yet dramatically different free testosterone values if one carries SHBG at 20 nmol/L and the other at 65 nmol/L. The man with the higher SHBG may experience frank hypogonadal symptoms despite a "normal" total level.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men states: "We suggest measuring free testosterone in men with total testosterone concentrations near the lower limit of the normal range, and in men with conditions that alter SHBG concentrations." [1]

How SHBG Drives Free Testosterone Fluctuation

SHBG rises with aging, hyperthyroidism, estrogen use, and hepatic disease. It falls with obesity, hyperinsulinemia, hypothyroidism, and nephrotic syndrome. Because SHBG acts as the primary buffer, a 20% rise in SHBG can drop free testosterone by a clinically meaningful margin even when total testosterone stays constant. This is exactly why rate-of-change analysis requires drawing SHBG simultaneously at every monitoring visit.

A 2020 cross-sectional study in the Journal of Clinical Endocrinology and Metabolism (N=9,054 men, ages 19 to 39) reported a median free testosterone of 70 pg/mL by equilibrium dialysis, with the 2.5th and 97.5th percentiles spanning 35 to 155 pg/mL in that age group. [2] The same paper confirmed that calculated free testosterone using the Vermeulen formula tracks equilibrium dialysis values with a bias of less than 5% across most of the physiologic range, making it acceptable when dialysis is unavailable.

Assay Differences That Skew Your Trend

The method used to measure free testosterone matters as much as the result itself. Analog immunoassay free testosterone is notoriously inaccurate and should not be used for clinical decision-making. Equilibrium dialysis is the gold standard. Calculated free testosterone from total testosterone, SHBG, and albumin via the Vermeulen or Sodergard equations is the next best option and is widely available.

If your laboratory switches assay methods between draws, your apparent rate of change may be entirely artifactual. Always confirm the method column on the lab report before interpreting a trend.

Reference Ranges and Optimal Zones

"Normal" and "optimal" are not synonyms. Reference ranges are derived from population distributions, typically the central 95%, and they include men who are sedentary, overweight, or have undiagnosed conditions. Optimal zones reflect the concentrations associated with the best clinical outcomes in controlled and observational data.

Men: Reference Range vs. Functional Target

The most widely cited reference interval for free testosterone in men, using equilibrium dialysis, spans roughly 44 to 244 pg/mL for adults aged 19 to 49. [2] The Endocrine Society recommends targeting a total testosterone mid-normal range during TRT, which typically corresponds to free testosterone between 150 to 224 pg/mL when measured by equilibrium dialysis in men without markedly elevated SHBG. [1]

For men on testosterone cypionate 100 mg injected weekly, the trough free testosterone (drawn immediately before the next injection) commonly falls 20 to 35% below the midpoint value. Clinicians using weekly injections should draw at trough and apply that correction mentally when comparing against peak-based reference ranges.

The Testosterone Trials (TTrials), a coordinated set of seven randomized controlled trials (N=788 men aged 65 and older with total testosterone <275 ng/dL), demonstrated that testosterone gel titrated to achieve mid-normal free testosterone improved sexual function, walking distance, bone density, and anemia scores versus placebo at 12 months. [3] Crucially, benefits were dose-dependent within the normal range, suggesting that simply reaching any value above the lower limit is insufficient.

Women: A Narrower and More Contested Range

Premenopausal women carry free testosterone in the range of 0.8 to 9.2 pg/mL by equilibrium dialysis, with concentrations roughly 10-fold lower than age-matched men. The Menopause Society (formerly NAMS) notes in its 2022 position statement that no validated lower threshold for female free testosterone exists that reliably predicts symptom onset or response to therapy. [4]

Postmenopausal women not on hormone therapy average free testosterone near 1.1 to 3.5 pg/mL. Women on oral estrogen therapy experience substantial SHBG elevation, sometimes doubling baseline SHBG, which can halve free testosterone even when total testosterone is unchanged. Transdermal estrogen causes far less SHBG elevation and is the preferred route for women in whom androgen status is being monitored.

Rate-of-Change Interpretation: The Core Clinical Framework

A single free testosterone value is a snapshot. Rate of change, calculated as the percentage difference between two consecutive draws taken under standardized conditions, is the movie. Most clinicians under-use this metric because labs do not automatically flag trends. You have to calculate it.

The framework below organizes rate-of-change findings into four clinical categories:

Category 1: Expected Therapeutic Rise (10 to 40% increase within 6 to 8 weeks of dose initiation or uptitration)

This is the target response when starting testosterone therapy or increasing a dose. A 15 to 25% rise in free testosterone over 6 to 8 weeks after a dose change is consistent with expected pharmacokinetics for testosterone cypionate or enanthate given weekly or biweekly. The 2018 Endocrine Society guideline recommends rechecking testosterone levels 3 to 6 months after initiation and at every subsequent dose adjustment. [1] Practically, the first recheck at 6 weeks catches early overshoot or undershoot before the patient completes three months of an incorrect dose.

Category 2: Unexpected Decline Despite Stable Dosing (>15% drop without a dose change)

This pattern should trigger a root-cause workup, not an automatic dose increase. Common causes include:

• Rising SHBG (new oral estrogen, hyperthyroidism, weight loss, new statin in some patients)
• Worsening injection technique with subcutaneous rather than intramuscular deposition, altering absorption kinetics
• Draw-time drift (patient drew earlier or later relative to last injection)
• Assay or laboratory methodology change
• Increased clearance from hepatic enzyme induction (rifampin, carbamazepine)

Order SHBG, albumin, TSH, and a liver panel before changing the testosterone dose in response to a decline.

Category 3: Supraphysiologic Rise (>40% above the upper reference limit)

Free testosterone above 244 pg/mL in men by equilibrium dialysis crosses into supraphysiologic territory. The Endocrine Society guideline explicitly recommends against targeting supraphysiologic values and states that testosterone should be "adjusted to maintain serum testosterone concentrations in the mid-normal range." [1] Values this high raise concerns for erythrocytosis, worsened sleep apnea, accelerated prostate growth, and cardiovascular risk.

The TRAVERSE trial (N=5,246 middle-aged and older men with hypogonadism and elevated cardiovascular risk, median follow-up 33 months) showed that testosterone gel increased hematocrit significantly versus placebo (rate ratio 3.69, P<0.001) and was associated with more pulmonary embolism and atrial fibrillation events, reinforcing the case against supraphysiologic dosing. [5] Hematocrit and free testosterone must be monitored together.

Category 4: Persistent Low Values Despite Adequate Dosing (<50% of lower reference limit)

When free testosterone stays low after documented dose administration and confirmed injection technique, the workup shifts toward absorption failure (for transdermal formulations), non-compliance, rapid metabolism, or marked SHBG elevation. Calculating the free testosterone-to-total testosterone ratio is useful here. A ratio below 1.5% in men with normal albumin strongly implies SHBG excess rather than inadequate total testosterone production.

How to Standardize Serial Draws for Valid Rate-of-Change Analysis

Rate-of-change calculations are meaningless if the two draws were taken under different conditions. The variables to standardize include:

Draw timing relative to dose. For weekly intramuscular testosterone, trough draw (morning before the next scheduled injection) produces the most reproducible result. Midpoint draw (3 to 4 days after weekly injection) captures peak-adjacent values and is preferred by some clinicians because it better represents average exposure. Either approach is acceptable, but switching between the two between draws invalidates comparison.

Time of day. Free testosterone follows a diurnal rhythm. Morning values (07:00 to 10:00) are 20 to 30% higher than afternoon values in untreated men. This rhythm attenuates, but does not disappear, during exogenous testosterone therapy. Always draw at the same time window.

Fasting status. Acute caloric restriction and significant weight change both shift SHBG within days. Drawing consistently in a fasted or consistently in a fed state removes one variable.

Laboratory constancy. Sending consecutive samples to the same laboratory using the same assay method is not optional. If a patient switches insurance and the new lab uses analog immunoassay instead of equilibrium dialysis, the resulting "change" is artifactual.

A 2019 analysis in Clinical Chemistry (N=412 men, two draws 8 weeks apart under standardized conditions) found a within-person coefficient of variation for equilibrium dialysis free testosterone of approximately 11%. [6] Any observed change smaller than 22% (two CVs) should be interpreted with caution because it may fall within biological and analytical noise.

Free Testosterone in Women: Monitoring During HRT and Androgen Therapy

Women receiving testosterone therapy for hypoactive sexual desire disorder (HSDD) or post-oophorectomy androgen insufficiency require the same rate-of-change discipline. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (published in 2019, co-authored by Endocrine Society, ISSWSH, BMS, and NAMS) recommends targeting the premenopausal physiologic range (free testosterone 0.8 to 9.2 pg/mL by equilibrium dialysis) and rechecking at 6 weeks and 3 to 6 months after starting therapy. [7]

The statement notes: "Measurement of free testosterone by equilibrium dialysis or calculated free testosterone is preferred over total testosterone alone in women because of the strong influence of SHBG on bioavailability." [7]

Oral Estrogen and SHBG: A Hidden Confounder

Women who switch from oral to transdermal estrogen during testosterone monitoring will show an apparent rise in free testosterone without any change in testosterone dose. Oral 17-beta estradiol at 1 to 2 mg/day roughly doubles SHBG in 4 to 6 weeks. Switching to a transdermal patch or gel reduces SHBG back toward baseline over the same interval, releasing previously bound testosterone and raising free testosterone by 30 to 60% in some patients.

This SHBG-mediated shift is not a dose adjustment signal. It is a route-of-administration effect. Documenting the estrogen formulation and dose at every draw prevents misinterpretation.

Rate-of-Change Targets Specific to Women

A therapeutic rise of 10 to 30% in free testosterone over 6 to 8 weeks after initiating subcutaneous testosterone pellet or topical testosterone is consistent with expected response in women. Values rising above the upper premenopausal reference limit (9.2 pg/mL by equilibrium dialysis) require dose reduction to avoid androgenic side effects including acne, hirsutism, and voice changes.

SHBG as the Rate-of-Change Modifier: A Practical Calculation

Because SHBG is the primary determinant of free testosterone fluctuation, tracking the SHBG trend alongside free testosterone makes rate-of-change interpretation far more specific. The Vermeulen calculated free testosterone formula is:

Free T (nmol/L) = Total T / (SHBG x (1 + Ka x Albumin) + 1)

Where Ka = 3.6 x 10^4 L/mol (albumin association constant) and albumin is assumed at 4.3 g/dL unless measured.

When free testosterone drops and SHBG has risen proportionally, the dose is almost certainly adequate. When free testosterone drops and SHBG is unchanged, the total testosterone production or absorption is the problem.

A cross-over pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism (N=54 hypogonadal men) found that free testosterone AUC varied by as much as 44% between individuals receiving identical testosterone cypionate doses, with SHBG level explaining 61% of that variance. [8] This single finding makes the case that SHBG measurement is not optional in rate-of-change monitoring.

TRT Dose Titration Protocol: What the Guidelines Actually Say

The Endocrine Society 2018 guideline on male hypogonadism specifies the following monitoring schedule after initiating testosterone therapy: [1]

1. Check testosterone (total and free), hematocrit, and PSA at 3 to 6 months after starting treatment.
2. If the total testosterone is in the mid-normal range and the patient reports symptom improvement, continue the current dose and recheck at 12 months.
3. If testosterone is outside the target range, adjust the dose and recheck at 6 weeks.
4. After two consecutive in-range values on stable dosing, annual monitoring is sufficient.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines on male hypogonadism add that free testosterone should be checked whenever SHBG is known or suspected to be abnormal, and that the titration target should consider free testosterone, not just total testosterone, in those cases. [9]

For testosterone gels and patches, morning steady-state draws (applied the night before) give the most representative value. For injections, the trough-to-peak free testosterone ratio should ideally stay below 2.5 to avoid peak-associated erythrocytosis and trough-associated symptomatic hypogonadism, which is an argument for more frequent smaller doses or long-acting formulations.

When Rate-of-Change Should Prompt Specialist Referral

Most rate-of-change findings are explained by the variables above. Some patterns warrant endocrinology or urology referral:

• Free testosterone declining progressively across three or more draws despite dose escalation, without a clear SHBG or compliance explanation
• Free testosterone persistently supraphysiologic at a dose that should be therapeutic, suggesting impaired clearance or SHBG suppression from an exogenous source
• New-onset decline in free testosterone in a man not on exogenous testosterone, especially if accompanied by rising LH and FSH (primary hypogonadism developing)
• Any free testosterone result above 300 pg/mL in a woman not prescribed testosterone

The American Urological Association guideline on evaluation and management of testosterone deficiency notes that patients with secondary hypogonadism (low testosterone with low or normal LH/FSH) require pituitary MRI to exclude a pituitary adenoma before initiating testosterone therapy. [10] Rate-of-change monitoring does not replace this structural evaluation.